BridgeBio Oncology Therapeutics Stock Price, News & Analysis
BBOT
NASDAQ
Company Description
Welcome to the overview page for BridgeBio Oncology Therapeutics (BBOT), where you can find comprehensive stock information and company updates.
Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.
Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.
Stock Performance
Latest News
SEC Filings
Financial Highlights
$0
Revenue (TTM)
-$44,757,000
Net Income (TTM)
-$1.03
-$70,626,454
Operating Cash Flow
13.33
-$49,181,000
Upcoming Events
DEC
10
December 10, 2025
Clinical
Preclinical poster presentation
Abstract 3568, Presentation PS2-12-06 at SABCS in San Antonio, TX; CT 5:00–6:30pm
DEC
12
December 12, 2025
Clinical
Trials-in-progress poster
Abstract 203, Presentation PS5-07-06 at SABCS in San Antonio, TX; CT 12:30–2:00pm
JAN
01
January 1, 2026 - June 30, 2026
Clinical
Phase 1 data readout
Initial clinical data from Phase 1 BREAKER-101 trial
JAN
01
January 1, 2026 - December 31, 2026
Clinical
Initial clinical data readouts
Anticipated initial clinical data for BBO-8520, BBO-10203, BBO-11818
JUL
01
July 1, 2026 - December 31, 2026
Clinical
Initial clinical data release
Expected initial clinical data release for Phase 1 KONQUER-101 trial
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of BridgeBio Oncology Therapeutics (BBOT)?
The current stock price of BridgeBio Oncology Therapeutics (BBOT) is $12.39 as of November 21, 2025.
What is the market cap of BridgeBio Oncology Therapeutics (BBOT)?
The market cap of BridgeBio Oncology Therapeutics (BBOT) is approximately 974.3M. Learn more about what market capitalization means .
What is the revenue (TTM) of BridgeBio Oncology Therapeutics (BBOT) stock?
The trailing twelve months (TTM) revenue of BridgeBio Oncology Therapeutics (BBOT) is $0.
What is the net income of BridgeBio Oncology Therapeutics (BBOT)?
The trailing twelve months (TTM) net income of BridgeBio Oncology Therapeutics (BBOT) is -$44,757,000.
What is the earnings per share (EPS) of BridgeBio Oncology Therapeutics (BBOT)?
The diluted earnings per share (EPS) of BridgeBio Oncology Therapeutics (BBOT) is -$1.03 on a trailing twelve months (TTM) basis. Learn more about EPS .
What is the operating cash flow of BridgeBio Oncology Therapeutics (BBOT)?
The operating cash flow of BridgeBio Oncology Therapeutics (BBOT) is -$70,626,454. Learn about cash flow.
What is the current ratio of BridgeBio Oncology Therapeutics (BBOT)?
The current ratio of BridgeBio Oncology Therapeutics (BBOT) is 13.33, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the operating income of BridgeBio Oncology Therapeutics (BBOT)?
The operating income of BridgeBio Oncology Therapeutics (BBOT) is -$49,181,000. Learn about operating income.